209 related articles for article (PubMed ID: 32388831)
1. Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech.
Seckin ZI; Whitwell JL; Utianski RL; Botha H; Ali F; Duffy JR; Clark HM; Machulda MM; Jordan LG; Min HK; Lowe VJ; Josephs KA
J Neurol; 2020 Sep; 267(9):2603-2611. PubMed ID: 32388831
[TBL] [Abstract][Full Text] [Related]
2. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in dopamine transporter uptake scans in progressive apraxia of speech.
Utianski RL; Trang Thu Pham N; Botha H; Ali F; Duffy JR; Clark HM; Lowe VJ; Whitwell JL; Josephs KA
Clin Park Relat Disord; 2023; 9():100207. PubMed ID: 37351017
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Extrastriatal
Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
[No Abstract] [Full Text] [Related]
5. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Antonini A; Benti R; De Notaris R; Tesei S; Zecchinelli A; Sacilotto G; Meucci N; Canesi M; Mariani C; Pezzoli G; Gerundini P
Neurol Sci; 2003 Oct; 24(3):149-50. PubMed ID: 14598060
[TBL] [Abstract][Full Text] [Related]
6. The Role of Dual-Phase 18 F-FP-CIT PET to Early Diagnosis of Corticobasal Syndrome.
Kim MS; Park DG; Shin IJ; An YS; Yoon JH
Clin Nucl Med; 2024 Feb; 49(2):124-130. PubMed ID: 38015725
[TBL] [Abstract][Full Text] [Related]
7. The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage.
Yoo HS; Chung SJ; Kim SJ; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1585-1595. PubMed ID: 29728749
[TBL] [Abstract][Full Text] [Related]
8. The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study.
Seckin ZI; Duffy JR; Strand EA; Clark HM; Utianski RL; Machulda MM; Botha H; Ali F; Thu Pham NT; Lowe VJ; Whitwell JL; Josephs KA
Parkinsonism Relat Disord; 2020 Dec; 81():34-40. PubMed ID: 33045651
[TBL] [Abstract][Full Text] [Related]
9. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
Im JH; Chung SJ; Kim JS; Lee MC
J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
[TBL] [Abstract][Full Text] [Related]
10. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy.
Lin WY; Lin KJ; Weng YH; Yen TC; Shen LH; Liao MH; Lu CS
Nucl Med Commun; 2010 Nov; 31(11):974-80. PubMed ID: 20717064
[TBL] [Abstract][Full Text] [Related]
11. Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies.
Kaasinen V; Kankare T; Joutsa J; Vahlberg T
J Nucl Med; 2019 Dec; 60(12):1757-1763. PubMed ID: 30979821
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT.
Morgan S; Kemp P; Booij J; Costa DC; Padayachee S; Lee L; Barber C; Carter J; Walker Z
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1063-70. PubMed ID: 22869921
[TBL] [Abstract][Full Text] [Related]
13. Undetectable specific striatal [¹²³I]-ioflupane binding in patients with parkinsonism.
Petyt G; Kreisler A; Demailly F; Olivier A; Defebvre L; Semah F
J Neurol Sci; 2014 Jun; 341(1-2):167-71. PubMed ID: 24814162
[TBL] [Abstract][Full Text] [Related]
14. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
[TBL] [Abstract][Full Text] [Related]
15. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
16. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
17. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
[TBL] [Abstract][Full Text] [Related]
18. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
[TBL] [Abstract][Full Text] [Related]
19. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone].
Mateos JJ; Lomeña F; Parellada E; Font M; Fernández E; Pavia J; Prats A; Bernardo M
Rev Esp Med Nucl; 2006; 25(3):159-65. PubMed ID: 16762269
[TBL] [Abstract][Full Text] [Related]
20. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
